Northern Trust Corp lifted its stake in shares of Epizyme Inc (NASDAQ:EPZM) by 10.6% in the fourth quarter, Holdings Channel reports. The fund owned 742,389 shares of the biopharmaceutical company’s stock after acquiring an additional 71,260 shares during the quarter. Northern Trust Corp’s holdings in Epizyme were worth $4,572,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quantamental Technologies LLC bought a new stake in shares of Epizyme during the 4th quarter worth $43,000. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of Epizyme during the 4th quarter worth $76,000. GSA Capital Partners LLP bought a new stake in shares of Epizyme during the 4th quarter worth $263,000. Virtus ETF Advisers LLC lifted its holdings in shares of Epizyme by 70.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 50,838 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 20,983 shares during the last quarter. Finally, MetLife Investment Advisors LLC lifted its holdings in shares of Epizyme by 50.5% during the 3rd quarter. MetLife Investment Advisors LLC now owns 37,738 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 12,663 shares during the last quarter. 72.63% of the stock is owned by institutional investors.
Epizyme stock opened at $12.68 on Monday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.37 and a beta of 3.14. Epizyme Inc has a twelve month low of $5.14 and a twelve month high of $18.70.
A number of research firms have recently issued reports on EPZM. BidaskClub downgraded shares of Epizyme from a “strong-buy” rating to a “buy” rating in a report on Friday, February 22nd. Oppenheimer dropped their price objective on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, February 27th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a report on Monday, January 7th. ValuEngine downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Finally, Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a report on Wednesday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $18.40.
ILLEGAL ACTIVITY NOTICE: “Epizyme Inc (EPZM) Shares Bought by Northern Trust Corp” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/epizyme-inc-epzm-shares-bought-by-northern-trust-corp.html.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Recommended Story: Understanding Market Liquidity
Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.